Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

Ditch the painkillers! While they can provide temporary relief, there are other ways to numb pain without medication. Find ...

In the second world war, the physician Henry Beecher observed that some of his soldier patients, despite being injured on the ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine), an oral NaV1.8 inhibitor, as a treatment for acute pain, representing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The FDA Approves A New, Non-Opioid Painkiller In January, the Food and Drug Administration approved a new pain medicine called Journavx (suzetrigine), made by Vertex Pharmaceuticals. It's the ...

The U.S. Food and Drug Administration said last week it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ... for its ambitious drug pipeline that involves winning FDA approval ...

The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA ...

Initially 2–3mg once daily; may adjust at intervals of at least 24hrs by 1mg/day. Usual range: 1–6mg/day; max 6mg/day. Elderly, debilitated, hypotensive, severe renal or hepatic impairment: 0 ...

Aging Health. 2011;7(6):813-828. Common opioid side effects reported in the literature include urinary retention, pruritus, nausea and vomiting, CNS effects and respiratory effects. The incidence ...